Deals Shaping the Medical Industry (04/2011)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.
You may also be interested in...
EU Business News: Biofarma Gets New PE Owners; Montefarmaco Strikes Ipsen Deal; Stada Expands Production Network
Round-up of the latest European consumer health market news: Private-equity firm Ardian acquires Italian supplements and cosmetics manufacturer Biofarma; Montefarmaco OTC strikes deal with Ipsen for GI lines; and Stada expands its production network with new Romania site.
The US FDA has published a raft of guidances on ANDA submissions and labeling updates as well as information requests and discipline review letters.
An advisory body to the UK government recommends a single-dose limit of 50 micrograms tetrahydrocannabinol (THC) for cannabidiol food products sold in the country. An analysis by Canna Consultants suggests this might translate in practice to today's widely assumed, although technically false, 0.2mg per retail unit limit.